ARWR
NASDAQArrowhead Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks460%
2026-04-192026-10-11
Mix2190d
- Other9(43%)
- Earnings4(19%)
- Analyst3(14%)
- SEC Filings2(10%)
- Insider2(10%)
- M&A1(5%)
Latest news
25 items- ANALYSTUBS resumed coverage on Arrowhead with a new price targetUBS resumed coverage of Arrowhead with a rating of Buy and set a new price target of $109.00
- PRArrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy VolunteersArrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injection ARO-MAPT demonstrates mean cerebrospinal fluid total tau reduction of 73% on Day 105, with a maximum individual reduction of 85%, supporting the potential for quarterly dosing Arrowhead will host a webinar today, October 14, at 2:30 PM ET/11:30 am PT to review additional interim results Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced interim results from an ongoing Phase 1/2a study of ARO-MAPT, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for Alzheimer’s disease an
- PRArrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia- FDA STAR pilot program aims to shorten the time from complete supplement submission to the action date to allow earlier patient access to therapies that address an unmet medical need Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that the United States Food and Drug Administration (FDA) has granted plozasiran entry in the Split Real Time Application Review (STAR) pilot program in connection with Arrowhead’s upcoming supplemental new drug application (sNDA) for severe hypertriglyceridemia (sHTG). SHTG is a condition that significantly increases the risk of acute pancreatitis, which is associated with repeated hospital admissions and can be fatal. The FDA STAR pilot progr
- PRArrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies– ARO-MAPT utilizes the Targeted RNAi Molecule (TRiM™) platform designed for subcutaneous administration and systemic delivery to the CNS by crossing the blood-brain barrier – Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced its plan to host an R&D webinar on Wednesday, October 14, 2026, at 11:30 AM PDT that will focus on investigational therapy ARO-MAPT and Arrowhead’s central nervous system (CNS) pipeline. The webinar will feature a presentation from Adam Boxer, M.D., Ph.D., Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF), where he directs the Neurosciences Clinical Research Unit and the Alzheimer's
- ANALYSTGoldman resumed coverage on Arrowhead with a new price targetGoldman resumed coverage of Arrowhead with a rating of Neutral and set a new price target of $74.00
- PRArrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia- ARO-DIMER-PA achieved deep and durable silencing of two genes with a single RNAi molecule - Mean maximal single dose reductions in serum PCSK9 of 72% and APOC3 of 88% - Clinical validation further demonstrates Arrowhead’s position as the leading innovator in siRNA therapies - Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subti
- ANALYSTCitigroup initiated coverage on Arrowhead with a new price targetCitigroup initiated coverage of Arrowhead with a rating of Buy and set a new price target of $108.00
- PRArrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor ConferencesArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming investor events: 2026 Cantor Global Healthcare Conference – September 9-11, 2026 Type: Fireside Chat Presentation Date/Time: September 10, 2026, 10:55 am EDT Morgan Stanley 24th Annual Global Healthcare Conference – September 14-16, 2026 Type: Fireside Chat Presentation Date/Time: September 15, 2026, 11:30 am EDT H.C. Wainwright 28th Annual Global Investment Conference – September 14-16, 2026 Type: Fireside Chat Presentation Date/Time: September 16, 2026, 9:00 am EDT Presentation materials and webcast links, if applicable, may be accessed on the Events an
- PRArrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia- Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population - - More than 90% of plozasiran-treated patients achieved triglycerides below thresholds for AP risk, 500 mg/dL at Month 12, and more than half achieved triglycerides below 150 mg/dL - - Plozasiran reduced cumulative acute pancreatitis (AP) events by 78% versus placebo in patients with TG above 500 mg/dL, with or without a prior history of AP - - Greater absolute benefit of AP risk reduction was observed in patients at higher risk - - In the highest-risk subgroup, patients with TG above 880 mg/dL and a prior history of AP, there was a 100% reduction in even
- PRArrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress- Detailed results from the Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia will be presented as a HOT LINE Late-Breaking Science Session on August 30, 2026 - - Arrowhead will host a webcast to review ESC data and Q&A on August 31, 2026 - Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will present important new data at the European Society of Cardiology Congress (ESC) in Munich, Germany. ESC 2026 Presentation Details Date & Time: Sunday, August 30, 2026, 17:30 CEST Session Title: HOT LINE 9 Late-breaking Science Session Location: Munich Auditorium-Hall B3 Title: Plozasiran in patients with severe hypertriglyceride
- INSIDERDirector Olukotun Adeoye Y sold $173,920 worth of shares (2,000 units at $86.96), decreasing direct ownership by 6% to 31,600 units (SEC Form 4)4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
- INSIDERDirector Perry Michael S sold $1,012,680 worth of shares (11,600 units at $87.30), decreasing direct ownership by 9% to 111,459 units (SEC Form 4)4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
- PRPeople Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce TriglyceridesREDEMPLO® (plozasiran) is listed in the Lauer-Taxe® database as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS), diagnosed either based on clinical symptoms alone or confirmed with a genetic test People living with this rare disease have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, often resulting in a reduced quality of life European marketing authorisation is based on positive results from the Phase 3 PALISADE study where plozasiran significantly reduced median fasting triglyceride levels at the 25 mg recommended dose from baseline to Mon
- SECSEC Form 10-Q filed by Arrowhead Pharmaceuticals Inc.10-Q - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
- SECArrowhead Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
- PRArrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results- Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss the results. "The recent period for Arrowhead included transformational events that support continued growth," said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. "We recently announced topline results from the SHASTA-3 and SHASTA-4 studies supporting our continued belief that plozasiran is a best-in-class molecule for patients with a spectrum of triglyceride disorder
- PRArrowhead Pharmaceuticals Acquires FDA Priority Review Voucher- Voucher to be used to accelerate review of a planned sNDA for plozasiran in severe hypertriglyceridemia Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has signed an agreement with an undisclosed third party to acquire a U.S. Food and Drug Administration (FDA) Rare Pediatric Disease Priority Review Voucher (PRV). The company intends to utilize the PRV for its upcoming Supplemental New Drug Application (sNDA) submission for plozasiran, anticipated before the end of 2026, to seek approval to expand the approved indication to include patients with severe hypertriglyceridemia (sHTG). SHTG is a condition that significantly increases the risk of acute pancreatitis, which
- PRArrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that as an inducement to entering into employment with the Company, on July 16, 2026, the Company’s Board of Directors approved "inducement" grants to 95 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 112,794 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans and vest annually over four years. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals (NASDAQ:ARWR) is a commercial-stage pharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause t
- PRArrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia- Study completion anticipated in mid-2027 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that leads to severely elevated low density lipoprotein-cholesterol (LDL-C) and early onset cardiovascular disease. Arrowhead anticipates that YOSEMITE will be completed in mid-2027 and, pending successful clinical results, intends to seek regulatory approval in multiple geographies thereafter. "Completing enro
- PRArrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe HypertriglyceridemiaDeep, durable, and consistent median triglyceride reductions of 79% and 81% from baseline in SHASTA-3 and SHASTA-4, respectively Statistically significant reduction in acute pancreatitis events versus placebo across the entire sHTG study population, with an unprecedented 100% event reduction in high-risk patients Continued and consistent safety and tolerability profile with no new safety signals Detailed results will be presented as a HOT LINE Late Breaker at the European Society of Cardiology (ESC) Congress on August 30, 2026 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced topline results for the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran
- PRArrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter ResultsArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on August 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 third quarter ended June 30, 2026.Webcast and Conference Call DetailsInvestors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call.For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BIe3d7a8269de14d348890ebe006a5b6a1. Once registered, you will receive th
- ANALYSTStifel initiated coverage on Arrowhead with a new price targetStifel initiated coverage of Arrowhead with a rating of Buy and set a new price target of $98.00
- PRArrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the conditionPeople living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing their quality of lifeMarketing authorisation is supported by positive Phase 3 PALISADE study data, in which 25 mg REDEMPLO demonstrated an 80% reduction in triglycerides from baseline and an 83% reduction in the incidence of acute pancreatitis in a pooled analysis of patients using all doses of REDEMPLO compared with placeboArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that the European
- PRArrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D WebinarsArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced its plan to host a 2026 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule (TRiM™) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company's clinical candidates and external key opinion leaders, who will discuss the respective disease areas and treatment landscapes. Part I of Arrowhead's 2026 Summer Series of R&D Webinars will focus on Arrowhead's cardiometabolic pipeline and will be held on June 29, 2026,
- INSIDERDirector Cohen Matthew Gregory was granted 11,882 shares (SEC Form 4)4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
ARWR FAQ
6 questionsWhat does Arrowhead Pharmaceuticals Inc. do?
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC...Where does ARWR stock trade?
Arrowhead Pharmaceuticals Inc. (ARWR) is listed on NASDAQ.What sector and industry is ARWR in?
Arrowhead Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ARWR?
Arrowhead Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-10-15. Recent price targets range from $2900.00 to $3100.00.What companies are similar to ARWR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ARWR side-by-side with any of them on Quantisnow.How can I track ARWR on Quantisnow?
Quantisnow aggregates Arrowhead Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARWR to receive live email and push alerts on every new disclosure.